Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
231.4 USD | -0.15% | -4.01% | -0.08% |
Apr. 24 | Market Share of Celltrion’s Remsima Rises to 74% in Europe | MT |
Apr. 22 | RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1 | MT |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.75 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 3.49 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.44% | 42.19B | B | ||
+44.30% | 40.15B | A | ||
-6.20% | 28.31B | C | ||
+5.59% | 24.63B | B- | ||
-23.59% | 18.2B | B | ||
+26.87% | 12.01B | C+ | ||
-3.55% | 11.76B | C+ | ||
+15.01% | 10.4B | B+ | ||
-4.86% | 9.94B | B+ | ||
-5.19% | 9.39B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IQV Stock
- Ratings Iqvia Holdings Inc.